Manning & Napier Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Manning & Napier Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.6K	Hold	170	–	–	﹤0.01%	452
2025 Q4	$10.1K	Hold	170	–	–	﹤0.01%	396
2025 Q3	$9.21K	Buy	+170	New	+$9.72K	﹤0.01%	403
2017 Q3	$192M	Sell	2,065,710 -52,776	-2%	-$4.66M	1.65%	20
2017 Q2	$192M	Buy	2,118,486 +426,016	+25%	+$38.8M	1.65%	21
2017 Q1	$149M	Sell	1,692,470 -335,460	-17%	-$29.8M	1.15%	37
2016 Q4	$168M	Buy	2,027,930 +1,885,520	+1,324%	+$162M	1.1%	35
2016 Q3	$13.2M	Buy	142,410 +2,490	+2%	+$234K	0.08%	95
2016 Q2	$10.9M	Buy	+139,920	New	+$11.9M	0.07%	112
2015 Q1	–	Sell	-288,180	Closed	-$26.1M	–	371
2014 Q4	$26.1M	Hold	288,180	–	–	0.12%	103
2014 Q3	$20.8M	Buy	288,180 +44,120	+18%	+$2.9M	0.09%	121
2014 Q2	$15.2M	Buy	244,060 +72,550	+42%	+$4.38M	0.06%	142
2014 Q1	$11.7M	Buy	+171,510	New	+$12.6M	0.05%	156

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Manning & Napier Advisors's BMRN Position: Q1 2026 in Review

Manning & Napier Advisors held its BioMarin Pharmaceuticals (BMRN) position steady in Q1 2026 at 170 shares worth $9.6K. The position accounts for ﹤0.01% of the portfolio, ranked #452.

Manning & Napier Advisors first reported a position in BMRN in Q1 2014 and has held it in 13 quarters since. The position peaked at $192M in Q2 2017. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Manning & Napier Advisors held 170 shares of BioMarin Pharmaceuticals worth $9.6K as of Q1 2026.
Manning & Napier Advisors left its BioMarin Pharmaceuticals share count unchanged in Q1 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q1 2026, its #452 holding.
Manning & Napier Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 13 quarters since.
Manning & Napier Advisors's BioMarin Pharmaceuticals position peaked at $192M in Q2 2017.
554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Manning & Napier Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.